Prenetics Global Limited (PRE)

NASDAQ: PRE · IEX Real-Time Price · USD
0.886
-0.016 (-1.80%)
At close: Jun 8, 2023, 3:26 PM
0.910
+0.024 (2.73%)
After-hours: Jun 8, 2023, 7:01 PM EDT
-1.8%
Market Cap 141.33M
Revenue (ttm) 201.42M
Net Income (ttm) -167.87M
Shares Out 159.55M
EPS (ttm) -1.73
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 134,858
Open 0.890
Previous Close 0.902
Day's Range 0.881 - 0.925
52-Week Range 0.700 - 4.900
Beta n/a
Analysts Buy
Price Target 7.00 (+690.25%)
Earnings Date Jun 5, 2023

About PRE

Prenetics Global Limited, an investment holding company, operates as a diagnostics and genetic testing company. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring system that allows users to take COVID-19 tests at point-of-care or at home utilizing the nucleic acid amplification test. The company's products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; Circle Medical, a diagnostic t... [Read more]

Sector Healthcare
Founded 2014
Employees 397
Stock Exchange NASDAQ
Ticker Symbol PRE
Full Company Profile

Financial Performance

In 2022, PRE's revenue was $275.76 million, a decrease of -0.03% compared to the previous year's $275.85 million. Losses were -$190.45 million, 9.45% more than in 2021.

Financial Statements

Analyst Forecast

According to one analyst, the rating for PRE stock is "Buy" and the 12-month stock price forecast is $7.0.

Price Target
$7.0
(690.25% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Prenetics Announces First Quarter 2023 Financial Results

HONG KONG, June 05, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics and precision oncology company, today announced financial results...

3 days ago - GlobeNewsWire

Prenetics Announces Fourth Quarter and Full Year 2022 Financial Results

New Business Strategy Focused on Precision Oncology New Business Strategy Focused on Precision Oncology

3 months ago - GlobeNewsWire

Prenetics Announces Formation of Scientific Advisory Board to Support New Business Strategy in Precision Oncology

LONDON and HONG KONG, March 02, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leader in genomic and diagnostic testing, is proud to announce the formation of a new Prenetics Scien...

3 months ago - GlobeNewsWire
}

Prenetics to Participate Virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

LONDON and HONG KONG, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leader in genomic and diagnostic testing, today announced that its management team will participate vi...

4 months ago - GlobeNewsWire

Prenetics Announces Dr. Bayju Thakar as Chief Executive Officer of Prenetics EMEA

LONDON and HONG KONG, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) a leader in genomic and diagnostic testing, today announced an executive leadership change to ensure the ...

5 months ago - GlobeNewsWire

Prenetics Global's stock rallies 82%

Shares of Prenetics Global Ltd. PRE, -2.11% jumped about 82% in premarket trading on Tuesday after the company said ActOnco's genomic test for tumors recently received clearance from the Food and Drug...

5 months ago - Market Watch

Prenetics Owned ACT Genomics Receives FDA Clearance for ACTOnco, the First Asia-Based Company to Receive Clearance for a Comprehensive Genomic Profiling Test for All Solid Tumors

LONDON and HONG KONG, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) a leader in genomic and diagnostic testing, today announced that ACT Genomics, a company which Prenetics ...

5 months ago - GlobeNewsWire

Prenetics Acquires ACT Genomics, Creating a Leader in Comprehensive Cancer Genetics and Precision Oncology

LONDON and HONG KONG, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leader in genomic and diagnostic testing, today announced that it is acquiring a majority stake in ACT...

6 months ago - GlobeNewsWire
}

Prenetics Announces US$20 Million Stock Repurchase Program and Inclusion into the MSCI Global Micro Cap Index

LONDON and HONG KONG, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a global leader in genomic and diagnostic testing, today announced that i...

6 months ago - GlobeNewsWire

Prenetics Announces Record Third Quarter 2022 Financial Results and Raises Full Year 2022 Revenue and EBITDA Guidance

LONDON and HONG KONG, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a global leader in genomic and diagnostic testing, today announced its un...

7 months ago - GlobeNewsWire

Prenetics Announces Second Quarter 2022 Financial Results and Raises Full Year Adjusted EBITDA Outlook

LONDON and HONG KONG, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a global leader in genomic and diagnostic testing, today announced its u...

9 months ago - GlobeNewsWire

Prenetics Announces First Quarter 2022 Financial Results After a Successful Listing on the Nasdaq under the Ticker “PRE.”

LONDON and HONG KONG, June 06, 2022 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a global leader in genomic and diagnostic testing, today announced its un...

1 year ago - GlobeNewsWire

Prenetics Rings the Opening Bell and Debuts on Nasdaq

LONDON and HONG KONG, May 18, 2022 (GLOBE NEWSWIRE) -- Prenetics Group Limited ("Prenetics" or the "Company"), a global leader in genomic and diagnostic testing, and Artisan Acquisition Corp. (Nasdaq:...

1 year ago - GlobeNewsWire
}